COVID-19’s impact on bioanalytical labs
Lavelle A & Micheli J | Bioanalysis, 13(15), 1169 – 1171, (2021)
Keywords: • bioanalysis • clinical trials • COVID-19 • NAAT • SARS-CoV-2 antigen • serology
The COVID-19 pandemic has presented unique challenges to the bioanalytical community. One year later, the impact of the pandemic on business practices, supply chains, timelines and project prioritization have been felt across the industry. Due to travel and personnel restrictions, laboratories have adapted their day to day lab operations and clinical trial practices. Logistically, supply chains have been affected, resulting in reduced availability of lab consumables, reagents, personal protective equipment (PPE) and biological matrices. The analytical needs for COVID-19 clinical trials are more varied than traditional therapeutic candidates as well, as each therapeutic can require pharmacokinetic, immunogenicity, biomarker and SARS-CoV-2 antigen and serological testing.
